

REC'D 04 JAN 2005

WIPO

PCT

PA 1249632

THE UNITED STATES OF AMERICA**TO ALL TO WHOM THESE PRESENTS SHALL COME:****UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**


November 18, 2004

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**

APPLICATION NUMBER: 60/509,073**FILING DATE: December 12, 2003****PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**



Trudie Wallace
TRUDIE WALLACE

Certifying Officer

NONPROVISIONAL PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400
Facsimile: (703) 836-2787

Attorney Docket No.: 118062

Date: December 12, 2003

MAIL STOP PATENT APPLICATION

Customer Number: 25944

**NONPROVISIONAL APPLICATION TRANSMITTAL
 RULE §1.53(b)**

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

22278 U.S. PTO
 107733348
 121203

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the nonprovisional patent application

For (Title): NOVEL COMPOUNDS AND THEIR USE IN THERAPY

By (Inventors): Pia KNUUTTILA, Harri SALO, Jussi TOMPERI, Siegfried WURSTER, Anna-Marja HOFFRÉN

- ☐ Formal drawings (Figs. ____; ____ sheets) are attached.
 - ☐ Use Figure ____ for front page of Publication.
- ☐ A Declaration and Power of Attorney is filed herewith.
- ☐ This application claims benefit of Provisional Application No. ____ filed ____.
- (A Preliminary Amendment is attached to reflect this claim in the Specification if not already present.)
- ☒ This patent application is assigned to OY JUVANTIA PHARMA LTD.
- ☐ The executed Assignment is filed herewith.
- ☐ An Information Disclosure Statement is filed herewith.
- ☒ Entitlement to small entity status is hereby asserted.
- ☒ A Preliminary Amendment is filed herewith.
- ☐ Priority of foreign application(s) No. ____ filed ____ in ____ is claimed (35 U.S.C. §119).
- ☐ A certified copy of the above corresponding foreign application(s) is filed herewith.
- ☐ This application is NOT to be published under 35 U.S.C. 122(b). The undersigned attorney or agent hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing.
- ☒ The filing fee is calculated below:

**CLAIMS IN THE APPLICATION AFTER ENTRY OF
 ANY PRELIMINARY AMENDMENT NOTED ABOVE**

FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	19 - 20	= *0
INDEP CLAIMS	1 - 3	= *0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

* If the difference is less than zero, enter "0".

SMALL ENTITY	
RATE	FEE
	\$ 385
x 9 =	\$
x 43 =	\$
+ 145 =	\$
TOTAL	\$ 385

OTHER THAN A SMALL ENTITY	
RATE	FEE
	\$ 770
x 18	\$
x 86	\$
+ 290	\$
TOTAL	\$

- ☒ Check No. 149237 in the amount of \$385 to cover the filing fee is attached. Except as otherwise noted herein, the Commissioner is hereby authorized to charge any other fees that may be required to complete this filing, or to credit any overpayment, to Deposit Account No. 15-0461. Two duplicate copies of this sheet are attached.

Respectfully submitted,

Thomas J. Pardini

James A. Oliff
 Registration No. 27,075

Thomas J. Pardini
 Registration No. 30,411

JAO:TJP/smk

NOVEL COMPOUNDS AND THEIR USE IN THERAPY

FIELD OF THE INVENTION

This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatment or prevention of diseases or conditions responding to selective SSTR1 active compounds. Moreover, the invention concerns methods of targeting a tissue bearing SSTR1s either for tissue imaging or as carriers for drugs to be transported to said tissue.

BACKGROUND OF THE INVENTION

The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details regarding the practice, are incorporated by reference.

Somatostatin is a cyclic peptide found endogenously in two major forms made up of 14 (SRIF-14) or 28 (SRIF-28) amino acids. The shorter SRIF-14 is identical in sequence to the C-terminal half of SRIF-28. Somatostatin is produced widely in the body and acts both systemically and locally to inhibit the secretion of various hormones, growth factors and neurotransmitters. The biological effects of somatostatin are mediated by a family of G protein-coupled receptors, of which five subtypes (SSTR1-5) have been cloned in humans (Reisine and Bell 1995; Patel 1999). The affinities of the two endogenous forms of somatostatin on the five subtypes are relatively similar, although SRIF-28 has been reported to have a moderate preference for the SSTR5. However, the five subtypes are differentially expressed in different tissues and do also show some differences in their interaction with a number of signalling pathways. Thus, the pleiotropic physiological responses mediated by somatostatin are a reflection of its widespread distribution and the existence of multiple receptor subtypes.

Based on their sequence similarities and their affinity profiles towards a number of octapeptide and hexapeptide somatostatin analogs, the

five subtypes in the somatostatin receptor family form two receptor subfamilies: one made up of SSTR2, SSTR3 and SSTR5 and another subfamily made up of SSTR1 and SSTR4. The former possesses high and the latter rather low affinity towards the aforementioned hexapeptide and octapeptide analogs (Hoyer et al. 1995). Due to the availability of high affinity and selective ligands, the physiology of the SSTR2,3,5 subfamily has been more thoroughly characterized and it appears that the 'classical' effects of somatostatin, such as very potent inhibition of growth hormone, insulin, glucagon and gastric acid release, are mediated either primarily or exclusively via members of this subfamily.

Even though the physiology and pathophysiology of the subtypes SSTR1 and SSTR4 are less well understood, a number of findings about the role of these subtypes have been described in scientific publications and the patent literature. US 6,124,256 reported that, given their localisation in the vascular wall and their time-related induction during the proliferative stage, SSTR1 and/or SSTR4 may be the optimal subtypes to prevent fibroproliferative vasculopathy via a somatostatin receptor based therapy. In agreement with this, Curtis et al. (2000) have described SSTR1 and SSTR4 to represent the predominant subtypes expressed in human blood vessels and have proposed the use of SSTR1- or SSTR4-selective agonists for the treatment of endothelial cell-mediated proliferative diseases. Aavik et al. (2002) have demonstrated that a purportedly SSTR1- and SSTR4-selective peptide analogue of somatostatin (CH-275) is able to prevent intimal hyperplasia after rat carotid denudation injury. Taken together, these findings may explain why two peptide analogues of somatostatin, octreotide and lanreotide, which possess very high preferences for the subtypes SSTR2 and SSTR5 but have rather low affinities for the subtypes SSTR1 or SSTR4, failed to show efficacy in clinical trials aiming at the prevention of restenosis after percutaneous transluminal angioplasty (Eriksen et al. 1995; van Essen et al. 1995).


Due to the fact that SSTR1 activation causes antiproliferative effects, SSTR1-selective agonists may be useful for the treatment of SSTR1 bearing tumors. For example, it has been described that SSTR1 receptors are

expressed in prostate cancer (Sinisi et al. 1997; Reubi et al. 1997; Reubi et al. 2001) but not in normal prostate tissue. Independent of its functional properties as an agonist or an antagonist, any SSTR1 selective ligand may be useful for the diagnosis of prostate tumors or tumors in other tissues expressing the SSTR1 subtype.

Somatostatin has a very short biological half-life and is therefore unsuitable for therapeutic use. A number of shorter hexa- and octapeptide analogs of somatostatin with improved biological stability have been identified (e.g. patent publications US 4,485,101, US 5,409,894 and WO 97/47317), but these abbreviated peptide analogs are heavily biased in favour of the SSTR2,3,5 subfamily and do not show any significant interaction with the subtypes SSTR1 or SSTR4. In contrast, WO 97/14715 and Rivier et al. (2001) describe a group of SSTR1 preferring undecapeptide agonists. However, besides their often rather short biological half-lives, peptides also possess other problematic properties, which make them unsatisfactory as medicines. For example, peptides have a very limited ability to penetrate membranes. This is one of the reasons, why it is in most cases impossible to apply peptides via an oral route and why peptides generally do not reach the central nervous system.

WO 97/03054 and US 6,221,870 describe benzo[g]quinoline-derived (WO 97/03054) or ergoline-derived (US 6,221,870) SSTR1-selective antagonist as lowering aggressive behavior in mice and, based on this observation, suggest such compounds to be useful for the treatment of depression, anxiety, affective disorders and attention deficit hyperactivity disorder.

Non-peptide somatostatin receptor ligands for all five somatostatin receptor subtypes have also been identified by Rohrer et al. (1998) through a strategy that consisted in the pharmacophore filtering of an existing compound collection in order to retrieve a subset of compounds which possessed structural features perceived to be critical for proper receptor-ligand interactions. The subsequent screening of this subset of compounds led to the discovery of an initial hit compound which then served as the starting point for



10 Importantly, the approach by Rohrer et al. (1998) relied on a
generally accepted structure-activity notion concerning the essential amino
acid residues in peptide analogs of somatostatin. By using a colour-coding
scheme highlighting moieties of different molecules corresponding to each
other, the authors of the paper make a particular point of emphasizing the fact
15 that the structure-activity-relationship known from peptides does also hold for
the peptidomimetics they discovered. It has long been recognized that the
dipeptide unit made up of the two residues 8 (tryptophan) and 9 (lysine) in
SRIF-14 are critical for high affinity binding to somatostatin receptors (cf Veber
et al. 1979). While the tryptophan residue in position 8 shows some degree of
20 flexibility, for example in that it can accommodate a D-Trp as well as an L-Trp
enantiomer (Meyers et al. 1978), the substitution of the lysine in position 9,
even by closely related basic amino acids such as ornithine or arginine, leads
to large losses in affinity (Rivier et al. 1976). On the other hand, modulating the

basic character of the lysine side chain by replacing it with a thialysine, a gamma- or a delta-fluorolysine did not result in a correlation between the pK_a 's of the side chains and the biological activities (Nutt et al. 1983). Based on this observation Nutt et al. (1983) concluded that deprotonation of the lysine side chain is not a requirement for biological activity. Kaupmann et al. (1995) went a step further and proposed a somatostatin receptor binding model, according to which a positive charge on lysine-9 in somatostatin actually is required in order to allow the formation of an ion pair with a negatively charged aspartate residue in the transmembrane domain 3 of the receptor. The fact that all five somatostatin receptor subtypes possess such a TM3 aspartate residue is in line with that proposal and suggests that the formation of an electrostatic interaction is a major contributor to the overall binding energy when a peptide analog of somatostatin or a peptidomimetic binds to somatostatin receptors. An important feature of the ligand-receptor interaction for somatostatin receptor would therefore appear to be analogous to the well-established binding model for biogenic amine receptor (Chen et al. 1999), according to which a high affinity ligand is required to contain a functional group that will provide for a positive charge when the ligand docks in the receptor binding site. The structure of all so far described molecules, which possess high affinity towards any of the five somatostatin receptor subtypes, independent of whether these molecules are peptides or peptidomimetics, are also supporting this binding interaction model, because all of these molecules contain a suitably basic functional group.

Surprisingly however, we have now found that the presence of a basic function that carries either a full or a partial positive charge at physiological pH values is not a mandatory requirement for a class of urea-based peptidomimetics in order for them to bind to the SSTR1 receptor. As a matter of fact, since it can be demonstrated that the presence or absence of such a basic function in molecules that are otherwise highly superimposable makes very little, if any, difference for their binding affinities on the SSTR1, it appears that at least this somatostatin receptor subtype is capable of operating in a binding mode that does not involve the formation of an ion pair between a

positive charge in the ligand and the negative charge of a highly conserved aspartate residue in TM3.

OBJECTS AND SUMMARY OF THE INVENTION

5 The object of the present invention is to provide novel compounds, or more specifically, novel urea-based peptidomimetics possessing a high degree of selectivity towards the somatostatin receptor subtype 1 (SSTR1). A particular object is to provide novel compounds, the binding interaction of which to the SSTR1 is independent of the presence or absence of a basic function at physiological pH values.

10 Thus, according to one aspect, this invention concerns a novel compound of formula I as defined hereinafter or a pharmaceutically acceptable salt or ester thereof.

15 According to another aspect, this invention concerns a pharmaceutical composition comprising as active ingredient a novel compound of formula I as defined hereinafter or a pharmaceutically acceptable salt or ester thereof, and at least one pharmaceutically acceptable carrier.


20 According to a third aspect, the invention concerns a compound of formula I as defined hereinafter or a pharmaceutically acceptable salt or ester thereof, for use in the manufacture of a pharmaceutical preparation for the treatment and/or prevention of a disease or condition responding to targeting with a selective SSTR1 compound.

25 According to a fourth aspect, the invention concerns the use of a compound of formula I as defined hereinafter or a pharmaceutically acceptable salt or ester thereof in combination with a detectable label, for targeting a tissue bearing SSTR1s for tissue imaging.

According to a fifth aspect, the invention concerns a compound of formula I as defined hereinafter or a pharmaceutically acceptable salt or ester thereof, for use as a carrier for another therapeutically active compound to be targeted to a tissue bearing SSTR1s.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides compounds of Formula I




(I)

or a pharmaceutically acceptable salt or ester thereof, wherein

X is

- 1) H,
- 2) aryl,
- 3) heteroaryl or
- 4) a group of formula



wherein aryl and heteroaryl can be unsubstituted or substituted with 1 to 4 substituents selected from R², as defined hereinafter;

Y is

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₃-C₇)cycloalkyl or
- 4) (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl;

Q is

- 1) aryl,
- 2) aryl-(C₁-C₆)alkyl,
- 3) heteroaryl or
- 4) heteroaryl-(C₁-C₆)alkyl;

wherein aryl and heteroaryl can be optionally substituted with 1 to 3 substituents selected from R²; and alkyl can be optionally substituted with Cy;

Cy is cycloalkyl, heterocyclyl, aryl or heteroaryl;

A is

- 1) (C₁-C₆)alkyl,
- 2) (C₂-C₆)alkenyl,
- 3) (C₂-C₆)alkynyl,
- 4) Cy or

5) Cy-(C₁-C₆)alkyl;

wherein alkyl and cycloalkyl can be optionally substituted with 1 to 2 substituents selected from R^c, as defined hereinafter; and Cy can be optionally substituted with 1 to 3 substituents selected from R^a;

5

B is

- 1) N or
- 2) C(D);

D is independently

10

- 1) H,
- 2) halogen,
- 3) (C₁-C₆)alkyl,
- 4) (C₂-C₆)alkenyl,
- 5) (C₂-C₆)alkynyl,
- 6) -NR^bR^b,
- 7) -NO₂ or
- 8) -CN;

15

wherein R^b is to be defined hereinafter;

E is

20

- 1) CH₂,
- 2) CHR^b or
- 3) CR^bR^c;

R1 is

25

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,
- 4) (C₂-C₆)alkynyl,
- 5) Cy,
- 6) Cy-(C₁-C₃)alkyl,
- 7) -(CH₂)_kC(O)NR^bR^b or
- 8) (C₁-C₆)alkoxy(C₁-C₆)alkyl;

30

wherein Cy can be unsubstituted or substituted with a group selected from R^a and alkyl, alkenyl, alkynyl and alkoxy can be unsubstituted or substituted with a group selected from R^c;

35

R2 is

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,

- 4) (C₂-C₆)alkynyl,
- 5) Cy.or
- 6) Cy-(C₁-C₃)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from R^a

- 5 and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from R^c;

R³ is

- 1) H or
- 2) (C₁-C₆)alkyl;

10

R^a is independently

- 1) H,
- 2) halogen,
- 3) (C₁-C₆)alkyl,
- 4) (C₂-C₆)alkenyl,
- 5) (C₂-C₆)alkynyl,
- 6) Cy,
- 7) -OR^b,
- 8) -SR^b,
- 9) -NR^bR^b,
- 10) -NR^bC(N)NR^bR^b,
- 11) -C(O)R^b,
- 12) -C(O)NR^bR^b,
- 13) -NC(O)R^b,
- 14) -SO₂NR^bR^b,
- 15) -NO₂,
- 16) -CN,
- 17) -CF₃ or
- 18) amino-(C₁-C₆)alkyl;

15

20

25

30

R^b is independently

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,
- 4) (C₂-C₆)alkynyl,
- 5) (C₂-C₇)cycloalkyl,
- 6) aryl,
- 7) heteroaryl,

35

or in the context of D, R¹, R^a and R^c, R^b and R^b together with the atom to which they are attached can also form a 5 to 6 membered ring containing 1 to 2 heteroatoms selected from N, O and S;

40

R^c is independently

- 1) H,
- 2) halogen,
- 3) Cy,
- 4) $-CN$,
- 5) $-OR^b$,
- 6) $-SR^b$,
- 7) $-NR^bR^b$ or
- 8) $-NR^bC(N)NR^bR^b$;

k is an integer 0 or 1;

h is an integer from 0 to 4;

n is an integer 0 or 1; and

m is an integer from 0 to 3.

"Alkyl", as well as other groups having the prefix "alk", such as alkoxy, alkanoyl, means carbon chains which may be linear or branched or combinations thereof. The size of the alkyl can further be specified by adding the number of carbons in front of the group, e.g. (C₁-C₆)alkyl, (C₁-C₃)alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, neo-pentyl, hexyl, heptyl, octyl, nonyl, and the like.

"Alkenyl" means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof. The size of the alkenyl can further be specified by adding the number of carbons in front of the group, e.g. (C₂-C₆)alkenyl, (C₂-C₃)alkenyl. Examples of alkenyl groups include, but are not limited to, vinyl, allyl, isopropenyl, 1-pentenyl, 2-pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

"Alkynyl" means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched or combinations thereof. The size of the alkynyl can further be specified by adding the number of carbons in front of the group, e.g. (C₂-C₆)alkynyl, (C₂-C₃)alkynyl. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptenyl, and the like.

"Alkoxy" refers to an "alkyl", as defined above, which is appended to the parent molecular moiety via $-O-$, i.e. an ether bond. The size of the alkyl in the alkoxy can further be specified by adding the number of carbons in front of

the group, e.g. (C₁-C₆)alkoxy. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, tert-butoxy, and the like.

"Cycloalkyl" means mono- or bicyclic saturated carbocyclic rings, each of which having from 3 to 8 carbon atoms. The term also includes
 5 monocyclic rings fused to an aryl group in which the point of attachment is on the non-aromatic portion. The size of the cycloalkyl can further be specified by adding the number of carbons in front of the group, e.g. (C₃-C₇)cycloalkyl, (C₅-C₁₀)cycloalkyl. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl,
 10 decahydronaphthyl, indanyl, and the like.

"Aryl" means mono- or bicyclic aromatic rings containing only carbon atoms. The term also includes aryl groups fused to a monocyclic
 cycloalkyl or monocyclic heterocyclyl group in which the point of attachment is on the aromatic portion. The size of the aryl can further be specified by adding
 15 the number of carbons in front of the group, e.g. (C₅-C₁₂)aryl. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydro-benzofuranyl, benzopyranyl, 1,4-benzodioxanyl, and the like.

"Heteroaryl" means a mono- or bicyclic aromatic ring containing at
 20 least one heteroatom selected from N, O and S, with each ring containing 5 to 6 atoms. The term also includes heteroaryl groups fused to a monocyclic cycloalkyl or monocyclic heterocyclyl group in which the point of attachment is on the aromatic portion. Examples of heteroaryl groups include, but are not limited to, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl,
 25 oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo(2,3b)pyridyl, quinolyl, indolyl, isoquinolyl, and the like.

"Heterocyclyl" means mono- or bicyclic saturated rings containing at
 30 least one heteroatom selected from N, O, S, each of said ring having from 5 to 8 atoms in which the point of attachment may be carbon or nitrogen. The term also includes monocyclic heterocycles fused to an aryl or a heteroaryl group in which the point of attachment is on the non-aromatic portion. Furthermore, the term also includes partially unsaturated monocyclic rings that are not aromatic,
 35 such as 2- and 4-pyridones attached through the nitrogen. Other examples of heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl,

piperazinyl, imidazolynyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, tetrahydroquinolynyl, tetrahydroisoquinolynyl, dihydroindanyl, and the like.

5 The term "cycloalkyl-alkyl", as employed herein, refers to a "cycloalkyl", as defined above, appended to the parent molecular moiety through an alkyl group, as defined above. The size of the cycloalkyl and the alkyl can further be specified by adding the number of carbons in front of the group, e.g. (C₃-C₇)cycloalkyl(C₁-C₆)alkyl, (C₃-C₆)cycloalkyl(C₁-C₂)alkyl. Examples of cycloalkyl-alkyl include, but are not limited to, cyclohexylmethyl, 1-cyclohexylethyl, 2-cyclopentylethyl, and the like.

10 The term "aryl-alkyl", as employed herein, refers to an "aryl", as defined above, appended to the parent molecular moiety through a (C₁-C₆)alkyl group, as defined above. The size of the aryl or alkyl can further be specified by adding the number of carbons in front of the group, e.g. aryl-(C₁-C₆)alkyl, (C₆-C₁₂)aryl-(C₁-C₃)alkyl. Examples of aryl-alkyl include, but are not limited to, 2-naphthylmethyl, 1-(2-indanyl)ethyl, 2-tetrahydronaphthylethyl, and the like.

15 The term "heteroaryl-alkyl", as employed herein, refers to a "heteroaryl", as defined above, appended to the parent molecular moiety through an alkyl group, as defined above. The size of the alkyl can further be specified by adding the number of carbons in front of the group, e.g. heteroaryl-(C₁-C₆)alkyl, heteroaryl-(C₁-C₂)alkyl. Examples of heteroaryl-alkyl include, but are not limited to, 2-(2-pyridyl)propyl, 2-benzothiophenylmethyl, 4-(2-quinolyl)butyl, and the like.

20 The term "Cy-alkyl", as employed herein, refers to a "Cy", as defined above, appended to the parent molecular moiety through an alkyl group, as defined above. The size of the alkyl can further be specified by adding the number of carbons in front of the group, e.g. Cy-(C₁-C₆)alkyl, Cy-(C₁-C₃)alkyl. Examples of Cy-alkyl include, but are not limited to, benzyl, 1-(2-naphthyl)ethyl, 2-cyclohexylethyl, and the like.

25 The term "alkoxy-alkyl", as employed herein, refers to at least one "alkoxy", as defined above, appended to the parent molecular moiety through an alkyl group, as defined above. The size of the alkoxy and alkyl can further be specified by adding the number of carbons in front of the groups, e.g. (C₁-C₃)alkoxy-(C₁-C₆)alkyl. Examples of alkoxy-alkyl include, but are not limited to, methoxymethyl, propoxyethyl, *tert*-butoxypentyl, 3,3-dimethoxypropyl, and the like.

The term "amino-alkyl", as employed herein, refers to at least one amino group (i.e. $-NH_2$ group), appended to the parent molecular moiety through an alkyl group, as defined above. The size of the alkyl can further be specified by adding the number of carbons in front of the group, e.g. amino-
5 (C₁-C₆)alkyl. Representative examples of amino-alkyl include, but are not limited to, aminomethyl, 2-aminoethyl, 1-aminoethyl, 2,2-diaminoethyl, 1-methyl-1-aminoethyl, and the like.

The term "halogen", as employed herein, refers to chlorine, bromine, fluorine or iodine.

10 The compounds of formula 1, as well as the pharmaceutically acceptable salts and esters thereof, are referred to below as the compounds of the invention, unless otherwise indicated.


The invention includes within its scope all possible stereoisomers of the compounds, including geometric isomers, e.g. Z and E isomers (*cis* and
15 *trans* isomers), and optical isomers, e.g. diastereomers and enantiomers. Furthermore, the invention includes in its scope both the individual isomers and any mixtures thereof, e.g. racemic mixtures. The individual isomers may be obtained using the corresponding isomeric forms of the starting materials or they may be separated after the preparation of a mixture of isomers according
20 to conventional separation methods, such as e.g. fractional crystallisation.

Some of the compounds may also exist as tautomers, namely having different points of attachment of hydrogen. For instance, ketones can exist also in their enol form (keto-enol tautomerism). The individual tautomers
25 as well as mixtures thereof are encompassed within the compounds of the invention.

Pharmaceutically acceptable salts, e.g. acid addition salts with both organic and inorganic acids are well known in the field of pharmaceuticals. Non-limiting examples of these salts include chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, citrates,
30 benzoates, salicylates and ascorbates. Pharmaceutically acceptable esters, when applicable, may be prepared by known methods using pharmaceutically acceptable acids that are conventional in the field of pharmaceuticals and that retain the pharmacological properties of the free form. Non-limiting examples of these esters include esters of aliphatic or aromatic alcohols, e.g. methyl,
35 ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl esters.


The compounds of the present invention possess selectivity towards the somatostatin receptor subtype 1 (SSTR1) and are therefore valuable for the treatment and/or prevention of diseases or conditions, where SSTR1 agonists or antagonists are indicated to be useful.

- 5 The compounds of the current invention can be viewed as consisting of two different motifs constructed around an 'aromatic amino acid'. The *N*-alpha of the 'aromatic amino acid' is part of a urea function whereas the remaining half of the urea is formed with a 'secondary amine' (motif No 1). The structure of the compounds of the invention is completed via amidation of the
- 10 'aromatic amino acid' with motif No 2. Thus, the compounds of the invention are named as amides wherein the selection of the core amide depends on the structure of the motif No 2, i.e. the core amide is either the motif No 2 or the amidated 'aromatic amino acid'. The naming is further exemplified with the following structures:



15

(2*R*, 2'*S*)-5-Amino-2-[3'-biphenyl-4-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide




(2*R*)-*N*-(3-Aminomethylcyclohexylmethyl)-2-(3,3-diphenethylureido)-3-naphthalen-1-ylpropionamide

One preferred embodiment of the compounds of the formula I are those wherein E is -CH₂-, m is an integer 2 and B is N.

5 Another preferred embodiment of the compounds of formula I are those wherein Q is aryl-(C₁-C₆)alkyl or heteroaryl-(C₁-C₆)alkyl, and even more preferably an aryl-methyl or a heteroaryl-methyl. For this purpose, a preferred aryl and heteroaryl is naphthyl and indoyl, which can be optionally substituted with 1 to 2 groups selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halogen and -

10 CF₃. Another preferred embodiment of the compounds of formula I are those wherein the carbon to which the substituent Q is attached has the absolute configuration *R*.

Yet another preferred embodiment of the compounds of formula I are those wherein Y is hydrogen and X is a group of formula



, wherein R₂ is as defined above or even more preferably, for this purpose R₂ is (C₁-C₆)alkyl substituted with a group selected from R^c.

Yet another preferred embodiment of the compounds of the formula I are those wherein R₂ is (C₁-C₆)alkyl.

20 Yet another preferred embodiment of the compounds of the formula I are those wherein n is 0.

Yet another preferred embodiment of the compounds of the formula I are those wherein h is 0.

25 The wording "SSTR1 selective" shall be understood to include compounds having a binding affinity constant K_i of at least 10 times better for the somatostatin receptor subtype 1 than for any of the other somatostatin receptor subtypes.

30 The term "treatment" or "treating" shall be understood to include complete curing of a disease or condition, as well as amelioration or alleviation of said disease or condition.

The term "prevention" shall be understood to include complete prevention, prophylaxis, as well as lowering the individual's risk of falling ill with said disease or condition.

Determination whether a certain compound is an SSTR1 agonist or an SSTR1 antagonist can be carried out according to known methods, such as those described by Sato et al. (1995) and Jasper et al. (1998).

Typical diseases or conditions that can be treated or prevented by the use of the compounds of this invention are

1. Indications relating to diseases or conditions of central nervous system, such as anxiety, depression, schizophrenia, attention deficit hyperactive disorder and neurodegenerative diseases such as dementia, Alzheimer's disease and Parkinson's disease. The affective disorders includes bipolar disorders, e.g. manic-depressive psychoses, extreme psychotic states e.g. mania and excessive mood swings for which a behavioural stabilization is being sought. The anxiety states include generalized anxiety as well as social anxiety, agoraphobia and those behavioural states characterized by social withdrawal, e.g. negative symptoms;
2. Diseases or conditions benefiting from the use of anti-proliferative agents (e.g. involving pathological vascular proliferation), such as angiogenesis, restenosis, smooth muscle proliferation, endothelial cell proliferation and new blood vessel sprouting or conditions involving neovascularization. The angiogenic disease may for example be age-related macular degeneration or vascular proliferation associated with surgical procedures, e.g. angioplasty and AV shunts. Other possible indications are the treatments of arteriosclerosis, plaque neovascularization, hypertrophic cardiomyopathy, myocardial angiogenesis, valvular disease, myocardial infarction, coronary collaterals, cerebral collaterals and ischemic limb angiogenesis;
3. Pathological conditions in the retina and/or iris-ciliary body, such as high intraocular pressure (IOP) and/or deep ocular infections. Such diseases may for instance be glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Other diseases connected to the eye may be ocular and corneal angiogenic conditions, for example, corneal graft rejection, retrolental fibroplasia, Osler-Webber Syndrome or rubeosis;

4. Diabetic complications, such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, Doan syndrome and orthostatic hypotension;
5. Cancers or excessive proliferation of normal or malignant tissue, such as the proliferation of adenoma cells, thyroid cancer, large bowel cancer, breast cancer, prostatic cancer, benign prostatic hyperplasia, small cell lung cancer, non-small cell cancer, pancreatic cancer, stomach cancer, GI tumors, cholangiocarcinoma, hepatic cancer, vesical cancer, ovarian cancer, melanoma, osteosarcoma, chondrosarcoma, malignant pheochromocytoma, neuroblastoma, brain tumors, thymoma, paragangliomas, prostate carcinomas, sarcomas, gastroenteropancreatic tumors, gastric carcinomas, phaeochromocytomas, ependymomas, renal cancers, leukemia e.g., leukemia of basophilic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin disease and non-Hodgkin lymphoma;
6. Or wound healing, ovulation, menstruation, placentation, peptic ulcers, psoriasis, rheumatoid arthritis and Crohn's disease.

It should be stressed that the diseases or conditions listed under points 1-6 above are examples only. The use of the compounds is not limited to treatment and/or prevention of said exemplified diseases or conditions.

It will be appreciated by the expert in the field, which indications would benefit from the use of an SSTR1 agonist and which ones will benefit from the use of an SSTR1 antagonist.

The compounds according to this invention can also be used for targeting a tissue bearing SSTR1s in tissue imaging for diagnostic purposes *in vitro* or *in vivo*. In this case the compound shall be coupled to a detectable label. Examples of such labels are different isotopes, such as ¹²³I, ¹²⁵I, ¹¹¹In, ¹¹C etc., or fluorescent labels. The label can be coupled directly to the compound or to a suitable spacer, which in turn is coupled to the compound. Brain, vessels and tumors are examples of tissues and organs that possess SSTR1 receptors and which thus could be imaged with SSTR1 selective compounds according to this invention.

The compounds according to this invention can also, based on their high affinity for the SSTR1 receptor, be used as carrier for another

therapeutically active compound to be targeted to tissues bearing SSTR1 receptors. Also in this case the other therapeutically active compound can be conjugated directly with the compound of this invention. Alternatively, said therapeutically active compound may be conjugated to a suitable spacer, which in turn is conjugated with the compound of this invention. This would offer a useful means for transporting e.g. anti-cancer drugs to tissues bearing SSTR1 receptors.

Preferred diseases or conditions to be treated or prevented with the compounds of the invention are anxiety, depression, schizophrenia, attention deficit hyperactive disorder and neurodegenerative diseases such as dementia, Alzheimer's disease and Parkinson's disease; and even more preferably schizophrenia.

Another group of preferred diseases or conditions to be treated or prevented with the compounds of the invention are cancers or excessive proliferation of normal or malignant tissue, and even more preferably prostatic cancer, benign prostatic hyperplasia, pancreatic cancer, thyroid cancer, brain tumors and GI tumors.

Another group of preferred diseases or conditions to be treated or prevented with the compounds of the invention are diabetic complications, and even more preferably diabetic retinopathy, diabetic nephropathy and diabetic neuropathy.

Yet other preferred diseases or conditions to be treated or prevented with the compounds of the invention are those involving pathological vascular proliferation, and even more preferably said disease or condition is angiogenesis, restenosis, smooth muscle proliferation, endothelial cell proliferation, new blood vessel sprouting or neovascularization.

The pharmaceutical compositions of the compounds of the invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients. Formulations may for instance enable oral, buccal, topical, intranasal, parenteral (e.g. intravenous, intramuscular or subcutaneous) or rectal administration or administration by inhalation or insufflation. Compounds of the invention may also be formulated for sustained delivery.

For oral administration, forms of suitable compositions include but are not limited to tablets, chewable tablets and capsules. These may be prepared by conventional means with pharmaceutically acceptable excipients,

such as binding agents (e.g. pregelatinized maize starch), disintegrants (e.g. potato starch), fillers (e.g. lactose) or lubricants (e.g. magnesium stearate). Tablets may be coated by methods well known in the art. For oral administration, possible liquid preparations include but are not limited to solutions, syrups or suspensions, or they may exist as dry powder for constitution with water or other suitable vehicle prior to use. These liquid preparations may be prepared by conventional means with pharmaceutically acceptable agents, such as suspending agents, non-aqueous vehicles, preservatives and emulsifiers.

- 5
- 10 A possible dose of the active compounds of the invention for oral, parenteral, buccal or topical dose to an adult human is between 0.1 and 500 mg of the active compound per unit dose, which may be administered, for instance, 1 to 4 times a day.

- 15 It is well recognized that the precise dose, the route of administration and the dosing interval can be determined by those skilled in the art. It is also well recognized that these variables depend on multiple factors including but not restricted to the activity of the therapeutic compound, the formulation thereof, pharmacokinetic properties (such as absorption, distribution, metabolism and excretion) of the therapeutic compound, the
- 20 nature and location of the target tissue or organ and the issues connected to the state of a disease or disorder in a patient in need of treatment. Additionally, when the compounds of the invention are administered with additional pharmaceutically active ingredients, one or more pharmaceutical compositions may be used for the delivery of all the agents, which may be administered
- 25 together, or at different times, as determined by those skilled in the art.

The invention will be illuminated by the following non-restrictive Experimental Part.


EXPERIMENTAL PART

List of abbreviations

	ACN	acetonitrile
	Boc	<i>tert</i> -butoxycarbonyl
5	BSA	bovine serum albumin
	CDCl ₃	deuterated chloroform
	CD ₃ OD	deuterated methanol
	DCM	dichloromethane
	DCC	dicyclohexylcarbodiimide
10	DIC	diisopropylcarbodiimide
	DIPEA	<i>N,N</i> -diisopropylethylamine
	DMF	<i>N,N</i> -dimethylformamide
	EDTA	ethylenediamine-tetraacetic acid
	ESI	electrospray ionization
15	Fmoc	9-fluorenylmethoxycarbonyl
	HATU	<i>O</i> -(7-azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
	HEPES	<i>N</i> -(2-hydroxyethyl)piperazine- <i>N'</i> -2-ethanesulfonic acid
	HOBt	1-hydroxybenzotriazole
20	HPLC	high performance liquid chromatography
	LC	liquid chromatography
	MS	mass spectrometry
	PG	protecting group
	RP-HPLC	reversed-phase high performance liquid chromatography
25	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
	TLC	thin layer chromatography
	TMOF	trimethyl orthoformate
	TMS	tetramethylsilane
30	TRIS	tris(hydroxymethyl)aminomethane


Compounds of the invention can be prepared using the following general synthetic schemes.

Scheme 1. Solid phase synthesis scheme I for the compounds of the invention




i) Removal of PG; ii) DIC, THF/DCM; iii) Ac₂O/pyridine/DCM; iv) DIC, DMF; v) 4-nitrophenyl chloroformate, DIPEA, THF/DCM (3:1); vi) urea formation by amine addition, DIPEA, DMF; vii) TFA/DCM

Scheme 2. Solid phase synthesis scheme II for the compounds of the invention.




- 5 i) DCM; ii) DIC, DMF; iii) removal of PG; iv) 4-nitrophenyl chloroformate, DIPEA, THF/DCM (3:1); v) urea formation by amine addition, DIPEA, DMF; vi) 3 % TFA/DCM. $r = 2-6$.

Scheme 3. Solution phase synthesis scheme for the compounds of the invention



- 6 i) DIC, HOBT, DMF/DCM ; ii) removal of PG; iii) 4-nitrophenyl chloroformate, DIPEA, THF(dry); iv) urea formation by amine addition, THF

Scheme 4. Building block synthesis scheme for secondary amines



- i) DCC, DCM; ii) 200°C (microwave), 10 min, neat; iii) 1M Borane-THF, THF, refluxing

It's evident for a person skilled in the art that the presented general schemes can be further modified for example by using different protecting groups (e.g. those described in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd ed. Wiley, 1991, New York, US), or by
5 adding or removing steps in between or after the described steps, which enable additional synthetic modifications to the examples given.

Starting materials

Rink and Trityl resins were obtained from Advanced ChemTech, UK. The amino acid derivatives were purchased from Novabiochem,
10 Switzerland and PepTech Co., USA. DIC, HOBt and piperidine were products of Acros Organics, Belgium. DIPEA was from Fluka AG, Germany. All the other reagents or solvents were purchased from Aldrich or Merck, Germany, if not otherwise specified. The reagents were used as such and solvents were purified and dried according to the methods described in W.L.F. Armareggo
15 and D.D. Perrin, "Purification of Laboratory Chemicals", 4th ed. Butterworth-Heinemann, 1996, Bath, Great Britain.

MS analysis

Molecular weights of the compounds were determined with a Micromass Micro triple quadrupole mass spectrometer. Essential MS
20 parameters were: cone voltage 30 V, capillary voltage 3.5 kV, low mass resolution on MS1 15, high mass resolution on MS1 15, ion energy on MS1 1.0, source temperature 110 °C, desolvation temperature 250 °C and desolvation gas flow 700 l/h. Samples were introduced by a Waters Alliance 2695 HPLC. Flow rate of 0.3 ml/min was formed of 10% water and 90% MeOH
25 eluent (containing 0.01% HCOOH). Sample volumes of 10 µl were injected through a Waters Symmetry Shield 2.1 X 10 mm C₁₈ precolumn.

LC-MS analysis

For LC-MS analysis the gradient started from 100% water (containing 0.01% HCOOH) (A) which was changed linearly over ten minutes
30 to 100% ACN (containing 0.01% HCOOH) (B). In addition, the Waters Symmetry Shield 2.1 X 50 mm C₁₈ column with a corresponding precolumn was flushed for two minutes with B. The flow rate was 0.4 ml/min and sample

volumes of 10 µl were injected. Some essential MS parameters were increased compared to standard MS analysis: desolvation temperature to 350°C and desolvation gas flow to 900 l/h. UV chromatograms were recorded with a Waters 996 diode array detector.

5 **NMR analysis**

NMR spectra for ¹H were recorded on a Bruker DMX 500 spectrometer operating at 500.13 MHz. CD₃OD or CDCl₃ were used as solvents and TMS as internal standard. In case of the product being a mixture of diastereomers, only the signals corresponding to one of the diastereomers are given.

10 **Flash Chromatography purification**

Flash Chromatographic purification was conducted with an Argonaut FlashMaster II Automated Purification System (Argonaut Technologies, UK) using normal phase columns (Supelco DSC-Si 20 g). The flow rate was 10 ml/min and the detection wavelength 254 nm. The standard elution program had a run time of 25 minutes with the following gradient: 100% DCM for 3 minutes, followed by gradual increase to 25% MeOH during 17 minutes and a gradual increase to 100% MeOH during the final 5 minutes. After MS verification, fractions containing the product were combined and evaporated.

20 **RP-HPLC purification**

Semi-preparative RP-HPLC purifications were done with a Waters 616 pump, controlled by a Waters 600 controller unit. The instrument was equipped with a Waters 2487 UV detector and a Waters fraction collector. An Xterra Prep C₁₈ RP 10 X 150 mm column with 7.8 X 20 mm precolumn was used for purifications. The flow rate was 6.6 ml/min and the detection wavelength 254 nm. The gradient started with water (containing 0.3% HCOOH) (A) and was linearly changed to ACN (containing 0.3% HCOOH) (B) within ten minutes. In addition, the column was flushed with B for two minutes. The fraction collector was programmed to collect 30 s fractions. The fractions were analysed by MS.

30 **LC purity analysis**

HPLC purity of the compounds was determined using a Waters 616 pump, controlled by a Waters 600 controller unit. The instrument was further

equipped with a Waters 2487 UV detector (detection wavelengths 254 nm and 220 nm). A Waters Symmetry Shield 2.1 X 50 mm C₁₈ column with a corresponding precolumn and a flow rate of 0.4 ml/min was used. A linear gradient starting with water (containing 0.01% HCOOH) (A) and ending with acetonitrile (containing 0.01% HCOOH) (B) over 17 minutes was applied, followed by maintaining solvent B for another minute.

Microwave reactions

Microwave assisted reactions were done in sealed, temperature-controlled and pressure-monitored reaction vessels in a Smith Creator microwave synthesis instrument from Personal Chemistry, Sweden. The instrument regulates the microwave power output according to the temperature and pressure achieved in the reaction vessel. Typical reaction times were around 10 minutes in a temperature of 200 °C.

Examples

The following representative compounds of the invention illustrate, but are not meant to limit, the scope of the invention.

Example 1

Synthesis of (2*R*, 2'*R*)-5-amino-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide.

Compound 1

Step I

Rink amide resin (0.8 g, 0.7 mmol/g, 0.56 mmol) was washed with DMF prior to use. Washed resin was dissolved in 40 ml of 20 vol-% piperidine in DMF and the mixture was agitated for 30 minutes. The piperidine treatment was repeated with fresh solution. The resin was then washed twice with DMF, twice with DCM and twice with diethyl ether.

Step II

N_α-Fmoc-N_ε-Boc-D-Ornithine (762.4 mg, 454.5 g/mol, 1.7 mmol, 3 eq) and DIC (266.4 μl, 126.2 g/mol, 0.806 g/cm³, 1.7 mmol, 3 eq) were dissolved in dry THF/DCM (1:1, 32 ml) and after 10 minutes mixed with the resin. After 8 hours of agitation, the solvent was filtered out and a fresh

solution of N_α -Fmoc- N_ϵ -Boc-D-Omithine and DIC in dry THF/DCM was introduced. After an additional 5 hours, the solvent was again filtered out.

Step III

5 Possibly unreacted amino groups of the resin were acetylated with a solution consisting of acetic anhydride (8 ml, 102.09 g/mol, 1.087 g/cm³, 85.2 μ mol) and pyridine (16 ml, 79.1 g/mol, 0.98 g/cm³, 0.20 mmol) in dry DCM (16 ml) for 30 minutes. The resin was then filtered and washed three times with DMF, three times with DCM, and three times with MeOH.

Step IV

10 The *N*- α -Fmoc protection of the attached ornithine was removed according to the procedure described in step I but without any washes prior to the treatment with piperidine/DMF.

Step V

15 Fmoc-3-naphthalen-1-yl-D-alanine (736.0 mg, 437.49 g/mol, 1.68 mmol, 3 eq) and DIC (266.4 μ l, 126.2 g/mol, 0.806 g/cm³, 1.7 mmol, 3 eq) were dissolved in dry DMF (32 ml) and after 10 minutes mixed with the resin. After 3 hours of agitation, the solvent was filtered out and a fresh solution of Fmoc-3-naphthalen-1-yl-D-alanine and DIC in dry DMF was introduced. After an additional 3 hours, the solvent was again filtered out.

20 **Step VI**

The *N*- α -Fmoc protection of the naphthylalanine attached in step V was removed according to the procedure described in step I but again without any washes prior to the treatment with piperidine/DMF.

Step VII

25 4-Nitrophenyl chloroformate (450.4 mg, 201.56 g/mol, 2.2 mmol, 4 eq) and DIPEA (384.0 μ l, 129.3 g/mol, 0.755 g/ml, 2.2 mmol, 4 eq) were dissolved in dry THF/DCM (3:1, 32 ml) and mixed with the resin. After two hours of agitation, the solvent was filtered and the resin washed once with DCM.

30 **Step VIII**

Phenethyl(2-pyridin-2-ylethyl)amine (example 16, 709.6 mg, 226.32 g/mol, 3.1 mmol, 5.6 eq) and DIPEA (336.0 μ l, 129.3 g/mol, 0.755 g/ml, 1.96 mmol, 3.5 eq) were dissolved in dry DMF (32 ml) and mixed with the resin. After overnight agitation, the solvent was filtered and the resin washed three times with DMF, three times with DCM and once with 3 vol-% TFA in DCM.

Step IX

The resin bound product was cleaved and the Boc protection removed by treating the resin with 50 vol-% TFA in DCM (32 ml) for 30 min after which the resulting red solution was collected and the resin was washed once with DCM. Water (8 ml) was added to the combined fractions and the solvents were evaporated. The product was purified using preparative RP-HPLC purification to obtain the title compound with 21 % yield.

MS-ESI⁺ (m/z): 581 [M+H]⁺, 291 [M+2H]²⁺

¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.40 (1H, m), 8.21 (1H, m), 7.86 (1H, d, J = 7.87 Hz), 7.75 (1H, d, J = 7.87 Hz), 7.69-7.65 (1H, m), 7.55 (1H, m), 7.49-7.46 (1H, m), 7.43 (1H, m), 7.38-7.35 (1H, m), 7.22-7.03 (7H, m), 4.59-4.56 (1H, m), 4.39 (1H, m), 3.69-3.65 (1H, m), 3.49-3.38 (2H, m), 3.32-3.25 (1H, m), 3.21-3.15 (1H, m), 2.92 (2H, m), 2.76 (2H, m), 2.59-2.56 (2H, m), 1.95-1.91 (1H, m), 1.74-1.67 (4H, m).

Example 2

Synthesis of (2R,2'R)-5-isopropylamino-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide, Compound 2

(2R,2'R)-5-Amino-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide (example 1, 38.7 mg, 580.73 g/mol, 66.6 μ mol) was dissolved in TMOF (0.5 ml) and DIPEA (15.6 μ l, 129.25 g/mol, 0.755 g/ml, 91.1 μ mol, 1.4 eq) was added. Acetic acid (7.0 μ l, 0.7 vol-% of tot.vol.) and acetone (7.0 μ l, 58.08 g/mol, 0.79 g/ml, 95.2 μ mol, 1.4 eq) were added and the mixture stirred for 15 min after which NaBH(OAc)₃ (25.5 mg, 211.94 g/mol, 0.12 mmol, 1.8 eq) in TMOF (0.5 ml) was added and the reaction mixture stirred over night. Unreacted NaBH(OAc)₃ was quenched with

a few drops of water and the mixture was evaporated to dryness. Water was added to the residue and the product was extracted with ethyl acetate. The combined fractions were dried over Na_2SO_4 . 30 mg of crude product was obtained and it was further purified using preparative RP-HPLC purification to obtain the title compound with 24 % yield.

MS-ESI⁺ (m/z): 623 [M+H]⁺, 312 [M+2H]²⁺

¹H NMR (500 MHz, CD_3OD , δ , ppm): 8.42 (1H, m), 8.25-8.22 (2H, m), 7.88 (1H, d, $J = 8.04$ Hz), 7.77 (1H, d, $J = 8.04$ Hz), 7.69-7.66 (1H, m), 7.58-7.55 (1H, m), 7.51-7.48 (1H, m), 7.45 (1H, m), 7.40-7.37 (1H, m), 7.23-7.20 (3H, m), 7.17-7.13 (1H, m), 7.10-7.05 (2H, m), 4.61-4.58 (1H, m), 4.44-4.41 (1H, m), 3.72-3.68 (1H, m), 3.52-3.48 (1H, m), 3.45-3.39 (1H, m), 3.36-3.26 (2H, m), 3.23-3.17 (1H, m), 3.23-3.17 (1H, m), 3.04-2.96 (2H, m), 2.79-2.76 (2H, m), 2.62-2.58 (2H, m), 1.98-1.93 (1H, m), 1.79-1.71 (3H, m), 1.30 (6H, d).

15 Example 3

Synthesis of (2S,2'R)-4-methylsulfanyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}butyramide, Compound 3

The synthesis was carried out as in example 1, except that in step II 20 Fmoc-L-methionine was used instead of N_α -Fmoc- N_ϵ -Boc-D-Ornithine. The product was purified using preparative RP-HPLC purification to obtain the title compound with 29 % yield.

MS-ESI⁺ (m/z): 598 [M+H]⁺

¹H NMR (500 MHz, CD_3OD , δ , ppm): 8.59 (1H, m), 8.22-8.19 (1H, m), 8.13 (1H, d, $J = 8.24$ Hz), 8.07 (1H, br s), 7.88 (1H, d, $J = 8.24$ Hz), 7.78 (1H, d, $J = 8.24$ Hz), 7.67 (1H, m), 7.63 (1H, m), 7.59-7.55 (1H, m), 7.52-7.49 (1H, m), 7.43-7.36 (2H, m), 7.28-7.24 (2H, m), 7.21-7.18 (1H, m), 7.14 (2H, m), 4.44-4.40 (1H, m), 4.25-4.22 (1H, m), 3.65-3.60 (1H, m), 3.50-3.29 (4H, m), 3.10-3.00 (2H, m), 2.77-2.68 (2H, m), 1.96 (3H, s), 1.94-1.81 (4H, m), 1.59-1.52 (1H, m).

30 Example 4

Synthesis of (2S,2'R)-3-methyl-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]butyramide, Compound 4

The synthesis was carried out as in example 1, except that in step II
5 Fmoc-L-valine was used instead of N_α-Fmoc-N_ε-Boc-D-Ornithine. The product was purified using preparative RP-HPLC purification to obtain the title compound with 22 % yield.

MS-ESI⁺ (m/z): 566 [M+H]⁺

¹H NMR (500 MHz, CD₃OD, δ, ppm): 8.54 (1H, m), 8.17 (1H, m),
10 8.11-8.07 (1H, m), 8.07 (1H, br s), 7.86 (1H, d, J = 7.86 Hz), 7.75 (1H, d, J = 7.86 Hz), 7.60-7.55 (2H, m), 7.50-7.47 (2H, m), 7.42-7.37 (2H, m), 7.24-7.21 (2H, m), 7.18-7.15 (1H, m), 7.08 (2H, m), 4.65-4.60 (1H, m), 4.10 (1H, m), 3.58-3.51 (2H, m), 3.45-3.33 (2H, m), 3.28-3.24 (2H, m), 2.98-2.95 (2H, m), 2.67-2.63 (2H, m), 2.04-1.97 (1H, m), 0.69 (6H, t).

15 Example 5

Synthesis of (2S,2'R)-2-[2'-[3,3-bis(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino]-4-methylsulfanylbutyramide, Compound 5

The synthesis was carried out as in example 1, except that in step II
Fmoc-L-methionine was used instead of N_α-Fmoc-N_ε-Boc-D-Ornithine and in
20 step VIII bis(2-pyridin-2-ylethyl)amine (example 17) was used instead of phenethyl(2-pyridin-2-ylethyl)amine. The product was purified using preparative RP-HPLC purification to obtain the title compound with 33 % yield.

MS-ESI⁺ (m/z): 599 [M+H]⁺, 300 [M+2H]²⁺

¹H NMR (500 MHz, CD₃OD, δ, ppm): 8.51 (2H, m), 8.15 (1H, m),
26 8.08 (1H, br s), 7.88-7.85 (3H, m), 7.78 (1H, m), 7.58-7.54 (1H, m), 7.51-7.48 (1H, m), 7.42-7.35 (6H, m), 4.47-4.44 (1H, m), 4.23 (1H, m), 3.61-3.44 (6H, m), 3.00-2.95 (4H, m), 1.99-1.92 (1H, m), 1.95 (3H, s), 1.89-1.79 (2H, m), 1.58-1.51 (1H, m).

Example 6

30 Synthesis of (2R)-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propanamide, Compound 6

The synthesis was carried out as in example 3, but without steps II and IV. Step III (capping) was done after step V (coupling of Fmoc-3-(1-naphthyl)-D-alanine to the resin). The product was purified using preparative RP-HPLC purification to obtain the title compound with 17 % yield.

5 MS-ESI⁺ (m/z): 467 [M+H]⁺

¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.45 (1H, m), 8.24 (1H, m), 8.07 (1H, br s), 7.87-7.84 (2H, m), 7.75 (1H, m), 7.56-7.53 (1H, m), 7.49-7.46 (1H, m), 7.44 (1H, m), 7.40-7.36 (2H, m), 7.25 (1H, m), 7.21-7.18 (2H, m), 7.15-7.12 (1H, m), 7.02 (2H, m), 4.69-4.66 (1H, m), 3.69-3.65 (1H, m), 3.45-3.34 (4H, m), 3.22-3.16 (1H, m), 2.87-2.78 (2H, m), 2.59-2.56 (2H, m).

Example 7

Synthesis of (2*R*,2'*R*)-5-amino-2-{2'-[3-(2-cyclohexylethyl)-3-(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino}pentanamide, Compound 7

15 The synthesis was carried out as in example 1, except that in step VIII (2-cyclohexylethyl)-(2-pyridin-2-ylethyl)amine (example 19) was used instead of phenethyl(2-pyridin-2-ylethyl)amine. The product was purified using preparative RP-HPLC purification to obtain the title compound with 21 % yield.

MS-ESI⁺ (m/z): 587 [M+H]⁺, 294 [M+2H]²⁺

20 ¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.43 (2H, m), 8.22 (1H, m), 7.88 (1H, m), 7.78 (1H, d, J = 7.81 Hz), 7.71-7.68 (1H, m), 7.58-7.55 (1H, m), 7.50 (1H, m), 7.43-7.38 (2H, m), 7.24 (1H, m), 7.15 (1H, m, J = 7.81 Hz), 4.59-56 (1H, m), 4.43-4.40 (1H, m), 3.72-3.68 (1H, m), 3.54-39 (3H, m), 3.07-3.00 (1H, m), 2.97-2.91 (2H, m), 2.86-2.83 (2H, m), 1.97-1.92 (1H, m), 1.77-1.53 (9H, m), 1.23-1.03 (6H, m), 0.83-0.76 (2H, m);

Example 8

Synthesis of (2*R*,2'*R*)-5-amino-2-{2'-[3-(2-dimethylaminoethyl)-3-(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylproplonylamino}pentanamide, Compound 8

30 The synthesis was carried out as in example 1, except that in step VIII *N,N*-dimethyl-*N'*-(2-pyridin-2-ylethyl)ethane-1,2-diamine (example 22) was used instead of phenethyl(2-pyridin-2-ylethyl)amine. The product was purified

using preparative RP-HPLC purification to obtain the title compound with 9 % yield.

MS-ESI⁺ (m/z): 549 [M+H]⁺, 275 [M+2H]²⁺

¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.45 (1H, m), 8.36 (2H, br s),
 5 8.23 (1H, m), 7.88 (1H, m), 7.78 (1H, m), 7.72-7.68 (1H, m), 7.58-7.55 (1H, m),
 7.52-7.49 (1H, m), 7.47-7.45 (1H, m), 7.40-7.37 (1H, m), 7.25 (1H, m), 7.11
 (1H, m), 4.61-4.58 (1H, m), 4.40-4.37 (1H, m), 3.75-3.71 (1H, m), 3.63-3.56
 (1H, m), 3.53-4.3 (3H, m), 3.38-3.5 (1H, m), 2.97-2.73 (6H, m), 2.64 (6H, s),
 1.98-1.92 (1H, m), 1.76-1.70 (3H, m);

10 Example 9

Synthesis of (2*R*,2'*R*)-5-amino-2-{2'-[3-[2-(4-aminophenyl)ethyl]-3-(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylproplonylamino}pentanamide, Compound 9

The synthesis was carried out as in example 1, except that in step
 15 VIII 4-[2-(2-pyridin-2-ylethylamino)ethyl]phenylamine was used instead of
 phenethyl(2-pyridin-2-ylethyl)amine. The product was purified using
 preparative RP-HPLC purification to obtain the title compound with 32 % yield.

MS-ESI⁺ (m/z): 597 [M+H]⁺, 299 [M+2H]²⁺

¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.42 (1H, m), 8.36 (1H, br s),
 20 8.23 (1H, m), 7.88 (1H, d, J = 7.89 Hz), 7.78 (1H, m), 7.69-7.66 (1H, m), 7.59-
 7.55 (1H, m), 7.52-7.48 (1H, m), 7.44 (1H, m), 7.40-7.37 (1H, m), 7.23-7.20
 (1H, m), 7.10 (1H, d, J = 7.89 Hz), 6.82 (2H, m), 6.62 (2H, m), 4.58-4.55 (1H,
 m), 4.40 (1H, m), 3.69-3.65 (1H, m), 3.51-3.38 (2H, m), 3.33-3.28 (1H, m),
 3.27-3.10 (2H, m), 2.94-2.91 (2H, m), 2.79-2.76 (2H, m), 2.50-2.46 (2H, m),
 25 1.97-1.91 (1H, m), 1.75-1.65 (3H, m);

Example 10

Synthesis of (2*R*)-*N*-(4-aminobutyl)-3-(1*H*-indol-3-yl)-2-[3-(3-phenylpropyl)-3-(2-pyridin-2-ylethyl)ureido]proplonamide, Compound 10

Step 1

30 Tritel chloride resin (0.15 g, 1.5 mmol/g, 0.225 mmol) was washed
 with DCM prior use. 1,4-Diaminobutane (0.226 ml, 88.15 g/mol, 0.877 g/ml,

2.25 mmol, 10 eq) in DCM (3 ml) was added to the resin and the mixture was agitated for 15 hours. The resin was then washed three times with DCM.

The subsequent steps in the synthesis were done as in example 1 steps V-IX, except that in step V N_α -Fmoc- N_{ϵ} -Boc-D-tryptophan was used instead of Fmoc-3-(1-naphthyl)-D-alanine and in step VIII (3-phenylpropyl)-(2-pyridin-2-ylethyl)amine (example 20) was used instead of phenethyl(2-pyridin-2-ylethyl)amine. In step VIII the TFA-wash was not carried out and cleavage from the resin was achieved with 25 % TFA in DCM to remove the Boc-protection from the tryptophan at the same time. The product was purified using preparative RP-HPLC purification to obtain the title compound with 31 % yield.

MS-ESI⁺ (m/z): 541 [M+H]⁺, 271 [M+2H]²⁺

¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.42 (1H, m), 7.83-7.80 (1H, m), 7.61 (1H, m), 7.39-7.36 (1H, m), 7.32 (1H, m), 7.25-7.13 (4H, m), 7.11 (5H, m), 4.46-4.43 (1H, m), 3.57-3.44 (2H, m), 3.30-3.05 (3H, m), 3.00-2.94 (1H, m), 2.89-2.85 (4H, m), 2.48-2.38 (2H, m), 1.69-1.45 (8H, m);

Example 11

Synthesis of (2*R*)-*N*-[2-(2-aminoethoxy)ethyl]-2-[3-butyl-3-(2-pyridin-2-ylethyl)ureido]-3-naphthalen-2-ylpropionamide, Compound 11

The synthesis was carried out as in example 10, except that 1,5-diamino-3-oxapentane was coupled to the resin instead of 1,4-diaminobutane. In step V Fmoc-3-(2-naphthyl)-D-alanine was used instead of N_α -Fmoc- N_{ϵ} -Boc-D-tryptophan and in step VIII butyl(2-pyridin-2-ylethyl)amine (example 21) was used instead of (3-phenylpropyl)-(2-pyridin-2-ylethyl)amine. Cleavage from the resin was done with 5 % TFA in DCM. The product was purified using preparative RP-HPLC purification to obtain the title compound with 37 % yield.

MS-ESI⁺ (m/z): 506 [M+H]⁺, 254 [M+2H]²⁺

¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.50 (1H, m), 7.86-7.75 (4H, m), 7.71 (1H, br s), 7.46-7.40 (4H, m), 7.27 (1H, m), 4.54-4.51 (1H, m), 3.61-3.44 (6H, m), 3.40 (2H, m), 3.33-3.29 (1H, m), 3.15-2.96 (5H, m), 2.93-2.90 (2H, m), 1.30-1.17 (2H, m), 1.14-1.06 (2H, m), 0.74-0.71 (3H, m).

Example 12

Synthesis of (2*R*)-*N*-benzyl-*N*-methyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide, Compound 12

Step I

Fmoc-3-naphthalen-1-yl-D-alanine (200.0 mg, 437.5 g/mol, 0.46 mmol, 1 eq) and DIPEA (79 μ l, 129.12 g/mol, 0.755 g/cm³, 0.46 mmol, 1 eq.) were dissolved in 1 ml of dry DCM. A solution of HATU (174 mg, 380.2 g/mol, 0.46 mmol, 1 eq.) in dry DCM (1 ml) was added and the mixture was stirred at ambient temperature for 15 minutes. A solution of *N*-methylbenzylamine (60 μ l, 121.8 g/mol, 0.94 g/cm³, 0.46 mmol, 1 eq) in dry DCM was added to the reaction mixture and the solution was stirred overnight at ambient temperature. 50 ml of DCM was then added to the reaction mixture and the mixture was washed twice with 20 ml of 5 % aq NaHCO₃. The organic phase was dried with Na₂SO₄ and evaporated. The compound was purified with flash chromatography yielding 0.211 g (85 %) of pure (2*R*)-Fmoc-2-amino-*N*-benzyl-*N*-methyl-3-naphthalen-1-ylpropionamide.

MS-ESI⁺ (m/z): 541 [M+H]⁺

Step II

(2*R*)-Fmoc-2-amino-*N*-benzyl-*N*-methyl-3-naphthalen-1-ylpropionamide (0.211 g, 540.7 g/mol, 39 mmol) was dissolved in 10 ml of 25 % (v/v) piperidine/ACN solution. After overnight stirring, the reaction mixture was evaporated and the product was purified with flash chromatography. The product, (2*R*)-2-amino-*N*-benzyl-*N*-methyl-3-naphthalen-1-ylpropionamide, was collected with a quantitative yield.

MS-ESI⁺ (m/z): 319 [M+H]⁺

Step III

(2*R*)-2-Amino-*N*-benzyl-*N*-methyl-3-naphthalen-1-ylpropionamide (65 mg, 318.4 g/mol, 0.20 mmol, 1 eq.) and DIPEA (35 μ l, 129.2 g/mol, 0.20 mmol, 1eq.) were dissolved in dry THF (2 ml) under argon. 4-Nitrophenyl chloroformate (42 mg, 201.6 g/mol, 0.20 mmol, 1 eq.) dissolved in 1 ml of dry THF was added to the stirred solution. After 40 minutes of stirring at ambient temperature, phenethyl(2-pyridin-2-ylethyl)amine (example 16, 92 mg, 226.3 g/mol, 0.40 mmol, 2 eq.) dissolved in 1 ml of dry THF was added to the reaction mixture. After 3 h, the mixture was evaporated to dryness, dissolved in ACN (0.5 ml) and purified with reversed phase flash chromatography, using an isocratic method (eluent 45 % aq ACN, column Supelco Discovery DSC-C18,

5g), which yielded 41 mg (36 %) of the product, (2*R*)-*N*-benzyl-*N*-methyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide.

MS-ESI⁺ (m/z): 571 [M+H]⁺

¹H NMR (500 MHz, CDCl₃, δ, ppm): 8.67-8.64 (1H, m), 8.35 (1H, d, J=8.1 Hz), 7.82 (d, 1H, J=7.9 Hz), 7.71 (1H, d, J=7.9 Hz), 7.60-7.56 (2H, m), 7.46 (1H, m), 7.36 (1H, m), 7.28 (4H, m), 7.22-7.19 (6H, m), 7.13 (3H, m), 4.36 (1H, m), 3.75-3.53 (4H, m), 3.46-3.21 (2H, m).

Example 13

Synthesis of (2*R*)-*N*-(1-phenylethyl)-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide, Compound 13

Step I

Fmoc-3-naphthalen-1-yl-D-alanine (200.0 mg, 437.5 g/mol, 0.46 mmol, 1 eq) and 1-phenylethylamine (60 μl, 121.8 g/mol, 0.94 g/cm³, 0.46 mmol, 1 eq) were coupled using the same coupling agents and procedure as described in step I of example 12. After flash chromatography, 157 mg (63 %) of (2*R*)-Fmoc-2-amino-3-naphthalen-1-yl-*N*-(1-phenylethyl)propionamide was obtained.

MS-ESI⁺ (m/z): 541 [M+H]⁺

Step II

(2*R*)-Fmoc-2-amino-3-naphthalen-1-yl-*N*-(1-phenylethyl)propionamide (157 mg, 540.7 g/mol, 0.29 mmol) was dissolved in a 20 % (v/v) piperidine/ACN solution. After overnight stirring at ambient temperature the solvents were evaporated and the product was purified with silica flash chromatography using isocratic elution with 5% MeOH in DCM. The purification gave 58 mg (63 %) of the product, (2*R*)-2-amino-3-naphthalen-1-yl-*N*-(1-phenylethyl)propionamide.

MS-ESI⁺ (m/z): 319 [M+H]⁺

Step III

(2*R*)-2-Amino-3-naphthalen-1-yl-*N*-(1-phenylethyl)propionamide (58 mg, 318.4 g/mol, 0.18 mmol, 1 eq) was reacted with 4-nitrophenyl chloroformate (37 mg, 201.6 g/mol, 0.18 mmol, 1 eq.) and phenethyl(2-pyridin-2-ylethyl)amine (example 16, 74 mg, 226.3 g/mol, 0.36 mmol, 2 eq.) to give the target urea compound as described in step III of example 12. After silica flash chromatography, 32 mg (31 %) of pure (2*R*)-3-naphthalen-1-yl-*N*-(1-phenylethyl)-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide was collected.

MS-ESI⁺ (m/z): 571 [M+H]⁺

¹H NMR (500 MHz, CDCl₃, δ , ppm): 8.45 (1H, m), 8.24 (1H, m), 7.81 (1H, m), 7.65-7.75 (1H, m), 7.53 (1H, m), 7.47 (2H, m), 7.38 (1H, m), 7.27-7.16 (7H, m), 7.11 (3H, m), 7.00-6.96 (3H, m), 4.98-4.89 (1H, m), 4.66 (1H, m), 3.56-3.49 (3H, m), 3.47-3.27 (3H, m), 2.87 (2H, m), 2.74 (2H, m), 1.31 (2H, d, J=6.8 Hz), 1.09 (1H, d, J=6.8 Hz).

Example 14

Synthesis of (2*R*)-*N*-cyclohexyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide, Compound 14

10 Step I

Fmoc-3-naphthalen-1-yl-D-alanine (200.0 mg, 437.5 g/mol, 0.46 mmol, 1 eq) and cyclohexylamine (52 μ l, 99.2 g/mol, 0.867 g/cm³, 0.46 mmol, 1 eq) were coupled using the same coupling agents and procedure as described in step I of example 12. After workup, the crude (2*R*)-Fmoc-2-amino-*N*-cyclohexyl-3-naphthalen-1-ylpropionamide was used in the next step without purification.

MS-ESI⁺ (m/z): 519 [M+H]⁺, 541 [M+Na]⁺

Step II

The crude product from step I was dissolved in a 20 % piperidine/DMF solution. After overnight stirring at ambient temperature the solvents were evaporated and the product was purified with silica flash chromatography as in step II in example 12. Pure fractions were pooled and evaporated giving 79 mg (58 % overall for steps I and II) of (2*R*)-2-amino-*N*-cyclohexyl-3-naphthylpropionamide.

25 Step III

(2*R*)-2-Amino-*N*-cyclohexyl-3-naphthalen-1-ylpropionamide (79 mg, 296.4 g/mol, 0.27 mmol, 1 eq.) was reacted with 4-nitrophenyl chloroformate (54 mg, 201.6 g/mol, 0.27 mmol, 1 eq.) and phenethyl(2-pyridin-2-ylethyl)amine, (example 16, 98 mg, 226.3 g/mol, 0.54 mmol, 2 eq.) to give the target urea compound as described in step III of example 12. After RP-HPLC purification, 51 mg (35 %) of pure (2*R*)-*N*-cyclohexyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide was collected.

MS-ESI⁺ (m/z): 549 [M+H]⁺

¹H NMR (500 MHz, CDCl₃, δ , ppm): 8.54 (1H, m), 8.29 (1H, m), 7.83 (1H, m), 7.73-7.71 (1H, m), 7.58-7.54 (2H, m), 7.49-7.46 (1H, m), 7.36 (2H, m), 7.28-7.26 (1H, m), 7.19 (1H, m), 7.15 (3H, m), 7.13-7.10 (1H, m), 7.07

(1H, m), 4.58 (1H, m), 3.45-3.39 (3H, m), 3.35-3.29 (3H, m), 2.93 (3H, m), 2.78 (3H, m), 1.68 (1H, m), 1.54-1.40 (5H, m), 1.27-1.16 (2H, m), 1.00 (1H, m), 0.87 (1H, m), 0.62 (1H, m).

Example 15

- 5 Synthesis of (2*R*)-*N*-isobutyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide, Compound 15

Step I

- 10 Fmoc-3-naphthalen-1-yl-D-alanine (200.0 mg, 437.5 g/mol, 0.46 mmol, 1 eq) and isobutylamine (47 μ l, 73.1 g/mol, 0.729 g/cm³, 0.46 mmol, 1 eq) were coupled using the same coupling agents and procedure as described in step I of example 12. After workup, the crude (2*R*)-Fmoc-2-amino-*N*-isobutyl-3-naphthalen-1-ylpropionamide was used for the next step without purification.

MS-ESI⁺ (m/z): 493 [M+H]⁺, 515 [M+Na]⁺

- 15 Step II

- 20 The crude product from step I was dissolved in a 20 % piperidine/MeOH solution. After overnight stirring at ambient temperature the solvents were evaporated and the product was purified with silica flash chromatography as in step II in example 12. Pure fractions were pooled and evaporated giving 64 mg (52 % overall for steps I and II) of (2*S*)-2-amino-*N*-isobutyl-3-naphthalen-1-ylpropionamide.

Step III

- 25 (2*R*)-2-Amino-*N*-isobutyl-3-naphthalen-1-ylpropionamide (79 mg, 296.4 g/mol, 0.27 mmol, 1 eq.) was reacted with 4-nitrophenyl chloroformate (54 mg, 201.6 g/mol, 0.27 mmol, 1 eq.) and phenethyl(2-pyridin-2-ylethyl)amine (example 16, 98 mg, 226.3 g/mol, 0.54 mmol, 2 eq.) to give the target urea compound as described in step III of example 12. After silica flash chromatography purification, 68 mg (60 %) of pure (2*R*)-*N*-isobutyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide was collected.

MS-ESI⁺ (m/z): 497 [M+H]⁺

- 35 ¹H NMR (500 MHz, CDCl₃, δ , ppm): 8.51 (1H, m), 8.23 (1H, m), 7.81 (1H, m), 7.71 (1H, d, J=7.67 Hz), 7.54 (2H, m), 7.46 (1H, tr, J=7.67 Hz), 7.39-7.32 (2H, m), 7.26-7.23 (2H, m), 7.19-7.16 (1H, m), 7.13-7.08 (3H, m), 7.02 (1H, d, J=7.67 Hz), 4.63 (1H, m), 3.58-3.45 (4H, m), 3.41-3.27 (2H, m),

2.93-2.83 (4H, m), 2.76-2.73 (2H, m), 1.50-1.43 (1H, m), 0.68 (3H, m), 0.64 (3H, m).

Following examples 16 to 22 describe the synthesis of building blocks required in the synthesis of the compounds of the invention.

Example 16

Synthesis of phenethyl(2-pyridin-2-ylethyl)amine, Compound 16

Step I

Phenylacetic acid (1.04 g, 136.15 g/mol, 7.6 mmol) was dissolved in DCM (15 ml). DCC (1.57 g, 206.33 g/mol, 7.6 mmol, 1 eq) was added and the mixture stirred for 30 min after which 2-(2-aminoethyl)pyridine (1.0 ml, 122.17 g/mol, 1.027 g/ml, 8.41 mmol, 1.1 eq) was added and the mixture stirred over night. The formed precipitate was filtered and the filtrate washed with water and dried over Na_2SO_4 . After evaporation, the product was purified using flash chromatography. The yield was 54 %.

Step II

The product from step I (0.93 g, 240.31 g/mol, 3.87 mmol) was dissolved in THF (20 ml) and BH_3 -THF complex (1 M, 11.6 ml, 3 eq) was added to reduce the carbonyl group. The reaction mixture was refluxed for two hours and then quenched by adding water (11.6 ml). The mixture was made acidic with conc. HCl (11.6 ml) and stirred for 30 min. The mixture was then made alkaline with NaOH solution (5M) and the product was extracted with ethyl acetate. Drying and evaporation of the organic fractions gave the title compound with 71 % yield.

MS-ESI⁺ (m/z): 227 [M+H]⁺

¹H NMR (500 MHz, CD_3OD , δ , ppm): 8.40 (1H, m), 7.73-7.70 (1H, m), 7.28-7.22 (4H, m), 7.17 (3H, m), 2.98-2.94 (4H, m), 2.88-2.85 (2H, m), 2.81-2.77 (2H, m).

Example 17

Synthesis of bis(2-pyridin-2-ylethyl)amine, Compound 17

Step I

Ethyl-2-pyridyl acetate (1.0 ml, 165.19 g/mol, 1.08 g/ml, 6.5 mmol) and 2-(2-aminoethyl)pyridine (0.80 ml, 122.17 g/mol, 1.027 g/ml, 6.7 mmol, 1.03 eq) were heated in a microwave oven at 200°C for 10 min. The product was purified using flash chromatography. The yield was 73 %.

Step II

Reduction was done as in example 16, except that 9 eq of borane-THF —complex was used. The yield was 41 %.

MS-ESI⁺ (m/z): 228 [M+H]⁺

5 ¹H NMR (500 MHz, CDCl₃, δ, ppm): 8.50 (2H, m), 7.58-7.55 (2H, m), 7.15 (2H, m), 7.11-7.08 (2H, m), 3.08-3.05 (4H, m), 2.99-2.96 (4H, m).

Example 18

Synthesis of 4-[2-(2-pyridin-2-ylethylamino)ethyl]phenylamine, Compound 18

10 The synthesis was carried out as in example 16, except that in step I 2-(4-aminophenyl)ethylamine was used instead of 2-(2-aminoethyl)pyridine. The yield for step I was 85 % and 88 % for step II.

MS-ESI⁺ (m/z): 242 [M+H]⁺

15 ¹H NMR (500 MHz, CD₃OD, δ, ppm): 8.35 (1H, m), 7.72-7.68 (1H, m), 7.24-7.20 (2H, m), 6.95-6.90 (2H, m), 6.68-6.61 (2H, m), 3.07-3.04 (2H, m), 2.97 (2H, m), 2.92-2.88 (2H, m), 2.72-2.69 (2H, m).

Example 19

Synthesis of (2-cyclohexylethyl)-(2-pyridin-2-ylethyl)amine, Compound 19

20 The synthesis was carried out as in example 17, except that in step I ethyl cyclohexylacetate (2 eq) was used instead of ethyl-2-pyridyl acetate. In step II 3 eq of borane-THF —complex were used. The yield for step I was 67 % and 31 % for step II.

MS-ESI⁺ (m/z): 233 [M+H]⁺

25 ¹H NMR (500 MHz, CD₃OD, δ, ppm): 8.44 (1H, m), 7.75-7.72 (1H, m), 7.31 (1H, m), 7.25-7.22 (1H, m), 2.95 (4H, m), 2.65-2.62 (2H, m), 1.70-1.67 (4H, m), 1.57 (1H, m), 1.41-1.37 (2H, m), 1.29-1.12 (4H, m), 0.95-0.87 (2H, m).

Example 20

Synthesis of (3-phenylpropyl)-(2-pyridin-2-ylethyl)amine, Compound

30 20

The synthesis was carried out as in example 16, except that in step I 3-phenylpropionic acid was used instead of phenylacetic acid. The yield for step I was 95 % and 64 % for step II.

MS-ESI⁺ (m/z): 241 [M+H]⁺

5 ¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.43 (1H, m), 7.74-7.70 (1H, m), 7.29-7.11 (7H, m), 2.96-2.89 (4H, m), 2.64-2.56 (4H, m), 1.83-1.77 (2H, m).

Example 21

Synthesis of butyl(2-pyridin-2-ylethyl)amine, Compound 21

10 The synthesis was carried out as in example 16, except that in step I butyric acid was used instead of phenylacetic acid. The yield for step I was 87 % and 49 % for step II.

MS-ESI⁺ (m/z): 179 [M+H]⁺

15 ¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.44 (1H, m), 7.75-7.72 (1H, m), 7.31 (1H, m), 7.26-7.23 (1H, m), 2.99 (4H, s), 2.68-2.65 (2H, m), 1.54-1.47 (2H, m), 1.38-1.28 (2H, m), 0.94-0.91 (3H, m).

Example 22

Synthesis of *N,N*-dimethyl-*N'*-(2-pyridin-2-ylethyl)ethane-1,2-diamine, Compound 22

20 The synthesis was carried out as in example 17, except that in step I 2-dimethylamino ethylamine (1 eq) was used instead of 2-(2-aminoethyl)pyridine. The yield for step I was 90 % and 57 % for step II.

MS-ESI⁺ (m/z): 194 [M+H]⁺

25 ¹H NMR (500 MHz, CD₃OD, δ , ppm): 8.47 (1H, m), 7.80-7.74 (1H, m), 7.41-7.25 (2H, m), 3.11-3.08 (2H, m), 3.05-3.01 (2H, m), 2.88-2.85 (2H, m), 2.58-2.54 (2H, m), 2.30 (3H, s), 2.28 (3H, s).

Example 23

30 Additional compounds (including but not restricted to those described below) were prepared according to methods described in the examples 1 to 22 by using corresponding starting materials.

Compound No.	Name	MS-ESI+ (m/z)	Example no.
23	(2 <i>R</i> , 2' <i>R</i>)-5-Guanidino-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide	624	1
24	(2 <i>R</i> , 2' <i>R</i>)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-3-pyridin-3-ylpropionamide	815	1
25	(2 <i>S</i> , 2' <i>R</i>)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-3-phenylpropionamide	614	1
26	(2 <i>S</i> , 2' <i>R</i>)-2-{2'-[3,3-Bis(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino}-4-methylpentanamide	581	1
27	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-{3'-naphthalen-1-yl-2'-[3-(3-phenylpropyl)-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide	595	1
28	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-{2'-[3-(4-methylbenzyl)-3-(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino}pentanamide	581	1
29	(2 <i>R</i> , 2' <i>R</i>)-3-(4-guanidinophenyl)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}propionamide	671	1
30	(2 <i>S</i> , 2' <i>R</i>)-3-(1 <i>H</i> -indol-3-yl)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}propionamide	653	1
31	(2 <i>R</i> , 2' <i>R</i>)-5-Guanidino-2-{3'-(1 <i>H</i> -indol-3-yl)-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide	812	1
32	(2 <i>R</i> , 2' <i>S</i>)-5-Amino-2-{3'-biphenyl-4-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide	607	1
33	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-{2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]-3'-phenylpropionylamino}pentanamide	631	1
34	(3 <i>S</i> , 2' <i>R</i>)-3-{3'-Naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-5-phenylpentanamide	642	1
35	(2 <i>S</i> , 2' <i>R</i>)-2-{ <i>N</i> -methyl-3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-3-phenylpropionamide	628	1
36	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-{3',3'-diphenyl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide	607	1
37	(2 <i>R</i>)- <i>N</i> -(3-Aminopropyl)-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide	524	10

38	(2 <i>R</i>)- <i>N</i> -(4-Aminomethylbenzyl)-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide	586	10
39	(2 <i>R</i>)- <i>N</i> -(2-Amino-1,1-dimethylethyl)-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide	538	10
40	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[2'-[3-butyl-3-(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino]pentanamide	533	1
41	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[3'-naphthalen-1-yl-2'-[3-(2-phenylpropyl)-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide	595	1
42	(2 <i>R</i>)-2-[3-[2-(2-Methoxyphenyl)ethyl]-3-(2-pyridin-2-ylethyl)ureido]-3-naphthalen-1-ylpropionamide	497	10
43	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[2'-[3-[3-(6-methylpyridin-2-yl)-propyl]-3-phenethylureido]-3'-naphthalen-1-ylpropionylamino]pentanamide	609	1
44	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[2'-[3-[3-(4-methylpiperazin-1-yl)propyl]-3-phenethylureido]-3'-naphthalen-1-ylpropionylamino]pentanamide	616	1
45	(2 <i>S</i> , 2' <i>R</i>)-4-Methylsulfanyl-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-pyridin-3-ylmethylureido]propionylamino]butyramide	584	1
46	(2 <i>R</i>)- <i>N</i> -(3-Aminomethylcyclohexylmethyl)-2-(3,3-diphenethylureido)-3-naphthalen-1-ylpropionamide	591	10
47	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[2'-[3-methyl-3-(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino]pentanamide	491	1
48	(2 <i>R</i>)-3-Naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-4-ylethyl)ureido]propionamide	487	1
49	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[2'-[3-(2-dimethylaminoethyl)-3-phenethylureido]-3'-naphthalen-1-ylpropionylamino]pentanamide	547	1
50	(2 <i>R</i>)-3-Naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-3-ylethyl)ureido]propionamide	487	1
51	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-pyridin-2-ylmethylureido]propionylamino]pentanamide	567	1
52	(2 <i>R</i> , 2' <i>R</i>)-5-Amino-2-[2'-[3-(6-methylpyridin-2-ylmethyl)-3-phenethylureido]-3'-naphthalen-1-ylpropionylamino]pentanamide	581	1
53	(2 <i>R</i> , 3' <i>R</i>)-5-Guanidino-2-[4'-naphthalen-1-yl-3'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]butylamino]pentanamide	637	1
54	(2 <i>R</i> , 2' <i>R</i>)-3-(1 <i>H</i> -imidazol-4-yl)-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionemino]propionamide	604	1

55	(2'R)-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamino]-3-piperidin-4-ylpropionamide	621	1
56	(2R, 2'R)-3-(1H-indol-3-yl)-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamino]propionamide	653	1
57	(2S, 2'R)-4-Hydroxy-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]butyramide	568	1
58	(2S, 2'R)-3-(4-Hydroxyphenyl)-2-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]propionamide	630	1
59	(3S, 2'R)-4-(1H-indol-3-yl)-3-[3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]butyramide	667	1
60	(2R, 2'R)-5-Amino-2-[3'-(4-benzoyloxyphenyl)-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide	637	1
61	(2R, 2'S)-5-Amino-2-[2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]-3'-pyridin-3-yl-propionylamino]pentanamide	532	1
62	(2R, 2'R)-5-Amino-2-[3'-(4-benzoylphenyl)-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino]pentanamide	635	1

Example 24

Binding affinity at the human somatostatin receptor subtypes

- The affinity of the compounds of the invention for the five human somatostatin receptor subtypes (SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5) was determined in competition binding assays with (¹²⁵I-Tyr)-[Leu⁸,DTrp²²]-somatostatin-28 (¹²⁵I-LTT-SRIF-28). The biological material for these experiments consisted of membranes from Chinese hamster ovary (CHO) cells stably transfected with one of the five human somatostatin receptor subtypes.
- Membranes (3-20 µg of total protein per sample) and trace amount of ¹²⁵I-LTT-SRIF-28 were incubated in 10 mM Hepes, 1 mM EDTA, 5 mM MgCl₂, 5 mg/ml of BSA and 30 µg/ml bacitracin, pH 7.6 with six concentrations of the compounds. Each concentration was run in duplicate. Non-specific binding was defined by 1 µM somatostatin-14 (SRIF-14) and corresponded to 5-25% of total binding. After 60 min at room temperature, incubations were terminated by rapid vacuum filtration through GF/B glass fiber filter mats (presoaked at 4°C in 200 ml of 10 mM Hepes, 1 mM EDTA, 5 mM MgCl₂, pH 7.6) and three 5 ml washes with ice-cold wash buffer (20 mM TRIS, 1 mM EDTA, 5 mM MgCl₂,

pH 7.4). The filters were then dried, impregnated with scintillate and the radioactivity was measured by scintillation counting. The analysis of the experiments was carried out by non-linear least square curve fitting. Affinity constants (K_i) were calculated from the IC_{50} -values according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973). Experiments were repeated a minimum of three times.

Using the aforementioned protocol, the following test results were obtained.

Compound	K_i (SSTR1) /nM	K_i (SSTR2) /nM	K_i (SSTR3) /nM	K_i (SSTR4) /nM	K_i (SSTR5) /nM
Compound 3	19 ± 1	>10000	>10000	640 ± 200	>10000
Compound 1	28 ± 4	>10000	>10000	890 ± 90	>10000
Compound 6	64 ± 10	>10000	>3000	550 ± 180	>10000

Besides these, a large set of compounds had a K_i -value less than 100 nM for SSTR1. Among this set were for example:

Compound 2
Compound 4
Compound 5
Compound 7
Compound 14
Compound 23
Compound 24
Compound 25
Compound 26
Compound 27
Compound 28
Compound 29
Compound 30

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention.

5 Thus, the described embodiments are illustrative and should not be construed as restrictive.

REFERENCES


- Aavik et al. (2002), *Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist*. FASEB J 16:724-6
- 5 • Chen L et al. (1999), *Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin*. Biochem. Biophys. Res. Com. 258:689-694
- Curtis et al. (2000), *Somatostatin receptor subtype expression and function in human vascular tissue*. Am J Physiol Heart Circ Physiol 278:H1815-1822
- 10 • Erksen et al. (1995), *Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty*. Am Heart J 130:1-8
- Hoyer et al. (1995), *Classification and nomenclature of somatostatin receptors*. TIPS 16:86-88
- 15 • Jasper JR et al. (1998), *Ligand efficacy and potency at recombinant α_2 -adrenergic receptors*. Biochem Pharmacol 55:1035-1043.
- Kaupmann et al. (1995), *Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor*. EMBO J. 14:727-735
- 20 • Meyers CA et al (1978), *Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography*. Biochemistry 17:2326-2330
- Nutt RF et al. (1983), *Somatostatin analogs which define the role of the lysine-9 amino group*. Int. J. Pept. Protein Res. 21:66-73
- 25 • Patel (1999), *Somatostatin and its receptor family*. Front Neuroendocrinol 20:157-198
- Reisine and Bell (1995), *Molecular biology of somatostatin receptors*. Endocrinological Reviews 16:427-442
- 30 • Reubi et al (1997), *A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors*. Eur J Pharmacol 345:103-110

- Reubi et al. (2001), *Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands*. Eur J Nucl Med 28:836-846
- 5 • Rivier et al. (2001), *Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1)*. J Med Chem 44:2238-2246
- Rivier J et al. (1976), *Hypothalamic hypophysiotropic hormones: review on the design of synthetic analogs*. In: Peptides 1976 (Loffet A, ed); Editions de L'Université Bruxelles, Belgium, pp 427-521
- 10 • Rohrer S et al. (1998), *Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry*. Science 282:737-740
- Sato M et al. (1995), *Factors determining specificity of signal transduction by G-protein-coupled receptors*. J Biol Chem 270:15269-15276
- 15 • Sinisi et al. (1997), *Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer*. J Clin Endocrinol Metab 82:2566-2569
- van Essen et al. (1997), *Effects of octreotide treatment on restenosis after coronary angioplasty: results of the VERAS study*. Circulation 20 96:1482-1487
- Veber DF et al. (1979), *Highly active cyclic and bicyclic somatostatin analogues of reduced ring size*. Nature 280:512-514

25

CLAIMS

1. A compound of formula (I)




(I)

or a pharmaceutically acceptable salt or ester thereof, wherein

X is

- 1) H,
- 2) aryl,
- 3) heteroaryl or
- 4) a group of formula



wherein aryl and heteroaryl can be unsubstituted or substituted with 1 to 4 substituents selected from R^a, as defined hereinafter;

Y is

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₃-C₇)cycloalkyl or
- 4) (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl;

Q is

- 1) aryl,
- 2) aryl-(C₁-C₆)alkyl,
- 3) heteroaryl or
- 4) heteroaryl-(C₁-C₆)alkyl;

wherein aryl and heteroaryl can be optionally substituted with 1 to 3 substituents selected from R^a; and alkyl can be optionally substituted with Cy;

Cy is cycloalkyl, heterocyclyl, aryl or heteroaryl;

A is

- 1) (C₁-C₆)alkyl,
- 2) (C₂-C₆)alkenyl,
- 3) (C₂-C₆)alkynyl,

- 4) Cy or
5) Cy-(C₁-C₆)alkyl;

wherein alkyl and cycloalkyl can be optionally substituted with 1 to 2 substituents selected from R^c, as defined hereinafter, and Cy can be optionally substituted with 1 to 3 substituents selected from R^a;

B is

- 1) N or
2) C(D);

D is independently

- 10 1) H,
2) halogen,
3) (C₁-C₆)alkyl,
4) (C₂-C₆)alkenyl,
5) (C₂-C₆)alkynyl,
15 6) -NR^bR^b,
7) -NO₂ or
8) -CN;

wherein R^b is to be defined hereinafter;

E is

- 20 1) CH₂,
2) CHR^b or
3) CR^bR^c;

R1 is

- 25 1) H,
2) (C₁-C₆)alkyl,
3) (C₂-C₆)alkenyl,
4) (C₂-C₆)alkynyl,
5) Cy,
6) Cy-(C₁-C₃)alkyl,
30 7) -(CH₂)_xC(O)NR^bR^b or
8) (C₁-C₆)alkoxy(C₁-C₆)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from R^a and alkyl, alkenyl, alkynyl and alkoxy can be unsubstituted or substituted with a group selected from R^c;

R2 is

- 1) H,
2) (C₁-C₆)alkyl,
3) (C₂-C₆)alkenyl,

- 4) (C₂-C₆)alkynyl,
- 5) Cy or
- 6) Cy-(C₁-C₃)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from R^a
 5 and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from R^a;

R³ is

- 1) H or
- 2) (C₁-C₆)alkyl;

10

R^a is independently

- 1) H,
- 2) halogen,
- 3) (C₁-C₆)alkyl,
- 4) (C₂-C₆)alkenyl,
- 5) (C₂-C₆)alkynyl,
- 6) Cy,
- 7) -OR^b,
- 8) -SR^b,
- 9) -NR^bR^b,
- 10) -NR^bC(N)NR^bR^b,
- 11) -C(O)R^b,
- 12) -C(O)NR^bR^b,
- 13) -NC(O)R^b,
- 14) -SO₂NR^bR^b,
- 15) -NO₂,
- 16) -CN,
- 17) -CF₃ or
- 18) amino-(C₁-C₆)alkyl;

15

20

25

30

R^b is independently

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,
- 4) (C₂-C₆)alkynyl,
- 5) (C₃-C₇)cycloalkyl,
- 6) aryl,
- 7) heteroaryl,

35

or in the context of D, R¹, R^a and R^c, R^b and R^b together with the atom to
 40 which they are attached can also form a 5 to 6 membered ring containing 1 to 2 heteroatoms selected from N, O and S;

R^c is independently

- 1) H,
- 2) halogen,
- 3) Cy,
- 4) $-CN$,
- 5) $-OR^b$,
- 6) $-SR^b$,
- 7) $-NR^bR^b$ or
- 8) $-NR^bC(N)NR^bR^b$;


k is an integer 0 or 1;

h is an integer from 0 to 4;

n is an integer 0 or 1;

m is an integer from 0 to 3;

with the proviso that the compound of formula I is not the compound




2. A compound according to claim 1, wherein

R^2 is

- 1) H,
- 2) (C_1-C_6) alkyl,
- 3) (C_2-C_6) alkenyl,
- 4) (C_2-C_6) alkynyl,
- 5) Cy or
- 6) $Cy-(C_1-C_3)$ alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from R^a and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from R^c .


3. A compound according to claim 1 or 2, wherein the compound is a compound of formula IA



IA

5 or a pharmaceutically acceptable salt or ester thereof,
wherein A, Q, X, Y and n are as defined in claim 1 or claim 2.

4. A compound according to claim 1 or 2, wherein the compound is a compound of formula IB



IB


10

or a pharmaceutically acceptable salt or ester thereof,
wherein A, D, E, X, Y, h, m and n are as defined in claim 1 or claim 2;

Q is aryl-(C₁)alkyl or heteroaryl-(C₁)alkyl, where aryl or heteroaryl are optionally substituted with 1 to 2 substituents selected from R^a.

15


5. A compound according to claim 1 or 2, wherein the compound is a compound of formula IC



IC

20 or a pharmaceutically acceptable salt or ester thereof,
wherein R₂, A, D, E, Q, h, m and n are as defined in claim 1.

6. A compound according to claim 1 or 2, wherein the compound is a compound of formula ID



5 or a pharmaceutically acceptable salt or ester thereof,

wherein A, X, D and h are as defined in claim 1 or claim 2;

Q is aryl-(C₁)alkyl or heteroaryl-(C₁)alkyl, where aryl or heteroaryl are optionally substituted with 1 to 2 substituents selected from R^a; and m is an integer 1 or 2.

10 7. A compound according to claim 1 or 2, wherein the compound of formula I is any of the compounds no 1 to 15 or 23 to 62 as described in the Examples.

8. A compound according to claim 1 or 2, wherein the compound of formula I is (2*R*,2'*R*)-5-amino-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide, (2*R*)-*N*-(4-aminobutyl)-3-(1*H*-indol-3-yl)-2-[3-(3-phenylpropyl)-3-(2-pyridin-2-ylethyl)ureido]propionamide, (2*S*,2'*R*)-2-{2-[3,3-bis(2-pyridin-2-ylethyl)ureido]-3-naphthalen-1-yl-propionylamino}-4-methylsulfanylbutyramide, (2*S*,2'*R*)-4-methylsulfanyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-butyramide, (2*S*,2'*R*)-3-methyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}butyramide, (2*R*)-*N*-cyclohexyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide or (2*S*,2'*R*)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]-propionylamino}-3-phenylpropionamide.

25 9. A compound according to any of the claims 1 to 8 where the compound is an SS₁ selective agonist.

10. A compound according to any of the claims 1 to 8 where the compound is an SS₁ selective antagonist.

11. A pharmaceutical composition comprising as active ingredient at least one compound according to any of the claims 1 to 10 and at least one pharmaceutically acceptable carrier.

12. Use of a compound according to any of the claims 1 to 10 for the manufacture of a pharmaceutical preparation for the treatment and/or prevention of a disease or condition responding to targeting with a selective SSTR1 compound.

13. The use according to claim 12, wherein the said disease or condition is a central nervous system disease or disorder, a disease or condition benefiting from the use of anti-proliferative agents, pathological condition in the retina and/or iris-ciliary body, diabetic complication, cancer or excessive proliferation of normal or malignant tissue.

14. The use according to claim 12, wherein the said disease or condition is anxiety, depression or schizophrenia.

15 15. The use according to claim 12, wherein the said disease or condition is prostatic cancer, benign prostatic hyperplasia, pancreatic cancer, thyroid cancer, brain tumor or gastro-intestinal tumor.

16. The use according to claim 12, wherein the said disease or condition is diabetic retinopathy, diabetic nephropathy or diabetic neuropathy.

20 17. The use according to claim 12, wherein the said disease or condition is angiogenesis, vascular restenosis, smooth muscle proliferation, endothelial cell proliferation, new blood vessel sprouting or neovascularization.

18. Use of a compound of according to any of the claims 1-10 in combination with a detectable label, for targeting tissues bearing SSSTR1s for tissue imaging.

19. Use of a compound of according to any of the claims 1-10 as a carrier for another therapeutically active compound to be targeted to tissues bearing SSTR1s.

ABSTRACT

This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of
5 said compounds for the treatment or prevention of diseases or conditions responding to SSTR1 active compounds. Moreover, the invention concerns methods of targeting a tissue bearing SSTR1s either for tissue imaging or as carriers for drugs to be transported to said tissue.

KOKON.SIUMÄÄRÄ 58